# Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Study · id `cardio:ct-nct03713684` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03713684](<https://clinicaltrials.gov/study/NCT03713684>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03713684

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 370 participants.

## Technical summary

Registry record NCT03713684. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-09 (actual); primary completion 2020-11-20 (actual). Results posted on 2021-12-02.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 370 participants (enrolled count; ClinicalTrials.gov record NCT03713684, source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)
- Started: 2018-11-09 (actual) (ClinicalTrials.gov record NCT03713684, source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)
- Primary completion: 2020-11-20 (actual) (ClinicalTrials.gov record NCT03713684, source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)
- Completion: 2021-01-04 (actual) (ClinicalTrials.gov record NCT03713684, source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)
- Results first posted: 2021-12-02 (ClinicalTrials.gov record NCT03713684, source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)
- Countries: United States; China; South Korea (ClinicalTrials.gov record NCT03713684, source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03713684-2021-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
- Acronym: AMPLITUDE-L
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Efpeglenatide SAR439977
- Intervention (Drug): Placebo
- Intervention (Drug): Background therapy
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Hanmi Pharmaceutical Company Limited
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: e1e8dcc71474ac5360306616bc923f80af9338c4ebb05be059133a02a7c70090
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
